Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Thymosin Beta-4 Fragment (TB4-Frag)
Overview
Thymosin Beta-4 Fragment refers to bioactive segments derived from the 43-amino acid thymosin beta-4 protein, most commonly a 7-amino acid N-terminal sequence (Ac-SDKP). These fragments retain specific biological activities of the parent peptide, including modulation of actin polymerization, angiogenesis, and inflammation.
Mechanism of Action
Shorter fragments may offer improved stability and targeted activity compared to full-length thymosin beta-4.
Research Summary & Key Findings
The tetrapeptide Ac-SDKP has been studied in rodent models of fibrosis and hypertension, demonstrating anti-inflammatory and antifibrotic effects. Preclinical wound healing models have shown enhanced angiogenesis and epithelialization with various TB4 fragments. Clinical evidence in humans remains limited to small exploratory studies without large-scale controlled trials.
Clinical Status
Thymosin Beta-4 Fragment (TB4-Frag) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Thymosin Beta-4 Fragment"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Thymosin Beta-4 Fragment"
Registered interventional and observational studies, including status and phase.
- PubChem: "Thymosin Beta-4 Fragment"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsNo lawful pathway today
Thymosin Beta-4 Fragment (TB4-Frag) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.